# AutScore – An integrative scoring approach for prioritization of ultra-rare autism spectrum disorder candidate variants from whole exome sequencing data

Apurba Shil <sup>1,2,3</sup>, Noa Arava<sup>2</sup>, Noam Levi <sup>1,2,3</sup>, Liron Levine <sup>4</sup>, Hava Golan <sup>2,3,5</sup>, Gal Meiri <sup>2,6</sup>, Analya Michaelovski<sup>2,7</sup>, Yair Tsadaka<sup>2,8</sup>, Adi Aran<sup>9,10</sup>, and Idan Menashe<sup>1,2,3\*</sup>

- <sup>1</sup> Department of Epidemiology, Biostatistics and Community Health Sciences, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
- <sup>2</sup> Azrieli National Centre for Autism and Neurodevelopment Research, Ben-Gurion University of the Negev. Beer Sheva, Israel
- <sup>3</sup> Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer Sheva, Israel
- <sup>4</sup> Bioinformatics Core Facility, Ben-Gurion University of the Negev, Beer-Sheva, Israel
- <sup>5</sup> Department of Physiology and Cell Biology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva. Israel
- <sup>6</sup> Preschool Psychiatric Unit, Soroka University Medical Center, Beer Sheva, Israel
- <sup>7</sup> Child Development Center, Soroka University Medical Center, Beer Sheva, Israel
- <sup>8</sup> Child Development Center, Ministry of Health, Be'er Sheva 84100, Israel.
- <sup>9</sup> Neuropediatric Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
- <sup>10</sup> Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

\* Correspondence: Prof. Idan Menashe, Email: idanmen@bgu.ac.il; tel.: +972-8-6477456

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### Abstract

**Background** Discerning clinically relevant ASD candidate variants from whole-exome sequencing (WES) data is complex, time-consuming, and labor-intensive. To this end, we developed *AutScore*, an integrative prioritization algorithm of ASD candidate variants from WES data, and assessed its performance to detect clinically relevant variants.

**Methods** We studied WES data from 581 ASD probands, and their parents registered in the Azrieli National Center database for Autism and Neurodevelopment Research. We focused on rare allele frequency <1%), high-quality proband-specific variants affecting genes associated with ASD or other neurodevelopmental disorders (NDDs). We assigned a score (i.e., *AutScore*) to each such variant based on their pathogenicity, clinical relevance, gene-disease association, and inheritance patterns. Finally, we compared the *AutScore* performance with the rating of clinical experts and the NDD variants prioritization algorithm, *AutoCasC*.

**Results** Overall, 1161 ultra-rare variants distributed in 687 genes in 441 ASD probands were evaluated by *AutScore* with scores ranging from -4 to 25, with a mean  $\pm$  SD of 5.89  $\pm$  4.18. *AutScore* cut-off of  $\geq$  12 outperforms *AutoCasC* in detecting clinically relevant ASD variants, with a detection accuracy rate of 72.3% and an overall diagnostic yield of 11.9%. Sixteen variants with *AutScore* of  $\geq$  12 were distributed in fifteen novel ASD genes.

**Conclusion** *AutScore* is an effective automated ranking system for ASD candidate variants that could be implemented in ASD clinical genetics pipelines.

Keywords AutScore, candidate variants, ASD, WES, prioritization algorithm.

#### 1 Introduction

Recent advances in high-throughput sequencing technologies have revolutionized genetic studies of complex diseases [1–7]. The emergence of next-generation sequencing (NGS) platforms has enabled genomic analyses at an unprecedented scale and resolution. These technologies have facilitated whole-genome sequencing (WGS) and whole-exome sequencing (WES) of large cohorts, unveiling novel disease-associated loci and providing deeper insights into the genetic architecture of complex disorders [1–9].

8 Detecting disease-causing variants from WES/WGS data is a complex task. Today, most 9 clinical genetics labs that analyze WES/WGS data follow the American College of Medical 10 Genetics and Genomics (ACMG) guidelines for interpreting sequence variants [10]. This mainly includes detecting high-quality variants with lower allele frequency and damaging 11 12 effects on the protein function. Other factors usually considered are the segregation of the 13 variant with the phenotype and existing evidence for the variant or gene association with the disease. To assist clinicians in this laborious process, several automated tools such as Exomiser 14 [11], AMELIE [12], LIRICAL [13], AutoCasC [14], etc., have been devised to prioritize 15 disease-specific variants (mainly single nucleotide variants [SNVs] and insertions/deletions 16 [indels]) from WES/WGS data. 17

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder that has greatly benefited from the emergence of NGS technologies. Recent large-scale WES and WGS studies have identified thousands of ASD susceptibility genetic variants in hundreds of genes [5,15–20]. Nevertheless, despite these advances in ASD genetics, clinically meaningful genetic variants are identified only in 8% to 30% of affected probands [5,21,22]. Thus, there is a need for new approaches to facilitate the detection of ASD-specific variants from WES/WGS data. Here, we present an automated scoring approach called *AutScore* that integrates variant and

25 gene-level information such as pathogenicity, deleteriousness, clinical relevance, gene-disease

association, and gene-variant inheritance pattern from a wide range of bioinformatics tools and
databases to generate a single score for prioritizing clinically relevant ASD candidate variants
from WES data for simplex and multiplex families. We applied the *AutScore* to WES data from
581 Israeli ASD-affected probands and their parents. We assessed its performance by
comparing the obtained results to a manual and blinded evaluation of the variants by clinicians
and to *AutoCasC* [14], an existing variant prioritization tool for neurodevelopmental disorders
(NDDs).

33

#### 34 Materials and Methods

#### 35 <u>Study Sample</u>

Our sample included 581 children diagnosed with ASD, registered with the Azrieli National Centre for Autism and Neurodevelopment Research (ANCAN) [23,24]. Based on clinical records, none of the parents had registered themselves with ASD, intellectual disability, or other neurodevelopmental disorders (NDDs). Genomic DNA was extracted from saliva samples from children and their parents using Oragene®•DNA (OG-500/575) collection kits (DNA Genotek, Canada).

#### 42 Whole Exome Sequencing (WES)

Whole Exome Sequencing (WES) analysis was conducted in two labs: (1) the Broad Institute as a part of the Autism Sequencing Consortium (ASC) project [25] and (2) the Clalit Health Services sequencing lab at Beilinson Hospital. WES was performed using Illumina HiSeq sequencers in both places, followed by the Illumina Nextera exome capture kit. The sequencing reads were aligned to human genome build 38 and aggregated into BAM/CRAM files. Then, the Genome Analysis Toolkit (GATK) [26] (Broad) or Illumina's DRAGEN pipeline [27] (Beilinson) was used for variant discovery and the generation of joint variant calling format

50 (vcf) files.

#### 51 Variant filtering and annotations

52 The multi-sample vcf files generated by the Genome Analysis Toolkit (GATK) and the DRAGEN platform were undertaken with identical procedures for variant filtering and 53 annotation, as previously detailed [28]. Subsequently, we identified pathogenic (P), likely 54 pathogenic (LP), or likely gene-disrupting (LGD) variants using the InterVar [29] tool in 55 conjunction with our proprietary tool, Psi-Variant [28]. We kept only those LP/P/LGD variants 56 that affected genes associated with ASD or other neurodevelopment disorders (NDDs) 57 according to the SFARI gene [30] or the DisGeNET [31] databases for downstream analyses. 58 Subsequently, 1161 candidate variants in 441 probands remained for further analysis (Fig. 1). 59

> Raw VCF Missing genotypes, probands with incomplete AF ≥ 1% and Low impact variants by VEP pedigree, and suspected probands removed (a) Inheritance filter GATK's "VQSR", "ExcessHet" (b) Remove compound variants filter and DRAGEN filter (c) Multiple (≥ 3) de-novo variants (d) Multiple (≥ 4) non-de-novo variants (e)  $GQ \le 50 \& DP \le 20$ Filtered VCF Apply InterVar & Psi-Keep variants distributed in ASD/NDD genes as per the Variant (I U P) DisGeNET or SFARI databases 1161 variants in 441 probands  $AutScore \ge 10$ 201 LP/P/LGD variants in 163 probands Clinical evaluation & IGV validation 116 ASD candidate variants in 98 probands

60

61 **Fig. 1** Analysis workflow for detecting ASD candidate variants from the WES data.

#### 62 Prioritization of ASD candidate variant

We developed a metric called *AutScore* to prioritize the detected list of ASD candidate variantsas follows:

65

AutScore = I + P + D + S + G + C + H

66 Where:

I – indicates the pathogenicity of a variant based on *InterVar* [29] classification as
follows: 'benign' = -3; 'likely benign' = -1; 'variants of uncertain significance (VUS)' = 0;
'likely pathogenic' = 3, and 'pathogenic' = 6.

70

• P – cumulatively assess the deleteriousness of a variant based on the following six insilico tools (SIFT [32] (< 0.05), PolyPhen-2 [33] ( $\geq$  0.15), CADD [34] (> 20), REVEL [35] (> 0.50), M\_CAP [36] (> 0.025) and MPC [37] ( $\geq$  2)). For each of these tools, a variant gets a score of 1 (deleterious) or 0 (benign), and these scores are aggregated to generate a single score ranging from 1 to 6.

76

D – indicates the agreement of variant-phenotype segregation with the predicted segregation by the Domino tool [38] where agreement with Domino's 'very likely dominant/recessive' classes = 2; agreement with Domino's 'likely dominant/recessive' classes = 1; disagreement with Domino's 'very likely dominant/recessive' classes = -2; disagreement with Domino's 'likely dominant/recessive' classes = -2; for variants with Domino's 'either dominant or recessive' segregation.

83

S – indicated the strength of association of the affected gene with ASD according to
the SFARI gene database [30] where 'high confidence' = 3; 'strong candidate' = 2;
'suggestive evidence' = 1; and not in SFARI database = 0.

87

G – indicated the strength of association of the affected gene with ASD according to 88 the DisGeNET database [31] where weak/no association (GDA=0 to 0.25) = 0: mild 89 90 association (GDA=0.25 to 0.50) = 1: moderate association (GDA=0.50-0.75) = 2: strong association (GDA=0.75 and above) = 3. 91 92 C – pathogenicity of a variant based on ClinVar [39] where 'benign' = -3; 'likely 93 benign' = -1; 'VUS' = 0; 'Likely pathogenic' = 1; 'Pathogenic' = 3. 94 95 H – segregation of variants in the family weighted as  $(n^2)$ -1 where n=number of 96 probands in a family that carries the detected variants. 97 Clinical genetics validation 98 99 Variants with AutScore  $\geq 10$  (top quartile of candidate variants scores) were visually validated 100 using the IGV software [40] and then manually examined by clinical geneticists according to 101 the standard ACMG/AMP guidelines [10]. The clinical experts assessed the likelihood of the 102 variants contributing to the ASD phenotype of the child and assigned each variant one of the 103 following rankings: 'Likely,' 'Possibly,' and 'Unlikely'. **Statistical Analysis** 104

We used a Receiver Operating Characteristic (ROC) analysis to assess the performance of *AutScore* in detecting ASD candidate variants using the clinical experts' rankings as the reference. We also accordingly compared the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. In addition, diagnostic yield (%) was computed as the proportion of the number of ASD probands that have at least one ASD candidate variant out of the total affected ASD probands that completed their WES analysis. We compared the performance of *AutScore* in detecting ASD candidate variants with the

performance of *AutoCasC* [14], an existing variant prioritization tool for NDDs. The agreement between *AutScore* and *AutoCasC* scores, and between these scores and the clinical assessment ranking, were assessed using Pearson's correlation and Cohen's Kappa statistic, respectively.

115 <u>Software</u>

116 Data storage, management, and analyses were conducted in a high-performing Linux cluster

using Python version 3.5 and R version 1.1.456. All statistical analyses and data visualization

118 were performed and incorporated into R.

#### 119 **Results**

A total of 1161 variants distributed in 687 genes in 441 ASD probands were evaluated by the *AutScore* algorithm. Variant's scores ranged from -4 to 25, with a mean  $\pm$  SD of 5.89  $\pm$  4.18 (Fig. 2). The clinical experts examined 201 (17.31%) variants with an *AutScore* of  $\geq$  10. Among these, 24 (11.9%) were suspected as false positive indels during the visual assessment using the IGV software and thus removed from subsequent analyses. Of the remaining 177 variants, 65 (36.7%) were ranked as 'likely,' 51 (28.8%) as 'possibly,' and 61 (34.5%) as 'unlikely' ASD candidate variants (Supplementary Table **S1**).

#### 127 Identifying an optimum AutScore cut-off

Two analyses were carried out to identify the optimal *AutScore* cut-off (Fig. 3). First, an ROC analysis using the clinical experts' ranking: "likely" as the true set of ASD candidate variants indicated that *AutScore* is an effective tool for detecting ASD clinically meaningful variants (AUC=0.843, 95% CI= 0.779-0.907) (Fig. 3A). Applying Yuden J's analysis to these data suggested that an *AutScore* of  $\geq$  12 would be the most effective cut-off (Yuden J=0.52). The same cut-off was also indicated by integrating detection accuracy and diagnostic yield (Max of Yield + Accuracy /10=17.04) (Fig. 3B).

135





Fig. 2 Histogram depicting the distribution of total LP/P/LGD variants assessed by AutScore (N=1161) 



151 Fig. 3 Assessing AutScore's optimal cut-off for detection of ASD susceptibility variants. A A receiver operating characteristics (ROC) analysis for different AutScore cut-offs. An arrow 152 153 indicates the best cut-off based on Yuden J's statistics. **B** Scatterplot of the detection accuracy

154 (x-axis) and the resulting diagnostic yield (Y-axis) for different *AutScore* cut-offs. An arrow
155 indicates the best cut-off based on both values' aggregated maximum.

#### 156 <u>Comparing AutScore with AutoCasC</u>

Next, we compared the performance of AutScore (using the selected cut-off  $\geq 12$ ) vis-à-vis the 157 existing NDD prioritization tool, AutoCasC, using its recommended cut-off of >6 [14], in 158 159 detecting ASD candidate variants (i.e., likely, possibly) (Fig. 4). A moderate, but statistically significant correlation (r=0.58; p<0.05) was observed between AutScore and AutoCasC. Both 160 tools had high sensitivity in detecting ASD variants using their recommended cut-off (0.91 and 161 162 0.92, respectively; Table 1). Yet, AutScore outperformed in all other diagnostic characteristics except in its diagnostic yield (Specificity: 0.616, PPV: 0.578 and Accuracy: 72.3%; 95% C.I: 163 164 65.1%-78.8% vs. Specificity: 0.133, and PPV: 0.397 Accuracy: 43.5%; 95% C.I: 35.9%-51.3% respectively) (Table 1). In addition, AutScore results had a better agreement with the clinical 165 expert rankings than those of the AutoCasC (percentage agreement =72.3% and Cohen's 166 167 Kappa= 0.468 vs. percentage agreement=43.5% and Cohen's Kappa= 0.04 respectively; Table 2). The variant list (n=177) with AutScore, clinical assessments, and AutoCasC values is 168 provided in Supplementary Table S1. 169

<b>Table 1</b> : Comparing the performance between <i>AutScore</i> ( $\geq 12$ ) and <i>AutoCasC</i> (> 6) in detecting ASD candidate variants								
Scoring Approaches	Sensitivity	Specificity	PPV	Accuracy (95% C.I.)	Diagnostic Yield (Likely)	Diagnostic Yield (Likely+Possibly)	Yuden J	
AutScore ( $\geq$ 12)	0.91	0.62	0.58	0.72 (0.65, 0.79)	9.81	11.9	0.52	
<i>AutoCasC</i> (> 6)	0.92	0.13	0.40	0.43 (0.36, 0.51)	9.98	15.5	0.06	
170								
171								
<b>Table 2</b> : Concordance between AutScore ( $\geq$ 12), AutoCasC (> 6), and Clinical Expert Rankings in detecting ASD candidate								

Combinations	Percentage Agreement	Cohen's Kappa (P-Value)
AutScore (≥ 12) Vs AutoCasC (> 6)	57.6	0.07 (0.20)
<i>AutScore</i> (≥ 12) Vs Clinical Assessment	72.3	0.45 (0.00)
Clinical Assessment Vs. AutoCasC (> 6)	43.5	0.04 (0.26)



Fig. 4 A clustered scatter diagram comparing the performance of *AutScore* (> 12), AutoCasC 172

(> 6), and the clinical assessments (e.g., likely (green), possibly (yellow), and unlikely (red)). 173

Characteristics of the LP/P/LGD variants detected by *AutScore* 174

Overall, 102 variants had an AutScore  $\geq$ 12. Of these, 59, 18, and 25 variants were ranked as 175 'likely', 'possibly', and 'unlikely' ASD candidate variants, respectively, by the clinical experts 176 177 (Table 3). Most of the detected variants (45.1%) were distributed in high-confidence ASD genes according to the SFARI Gene database [30] (i.e., SFARI score of 1). Another 29 (28.4%) 178 179 variants were detected in 23 genes (29.9%) not listed in the SFARI database and thus may be 180 considered novel ASD genes. More than 90% of the detected variants were classified as LP/P

#### according to the ACMG/AMP variant interpretation criteria [10], and more than 62% were

#### 182 denovo variants.

<b>Table 3:</b> Characteristics of the detected variants with $AutScore \ge 12$ (N=102)				
Functional Consequences	<b>Freq (%)</b>			
Frameshift Insertion/Deletion	25 (24.5%)			
Splice Acceptor/Donor	6 (5.9%)			
Stop Gained/Lost	22 (21.6%)			
Missense	37 (36.3%)			
Other	12 (11.8%)			
Gene Type				
SFARI 1	46 (45.1%)			
SFARI 2 and 3	27 (26.5%)			
Any SFARI	73 (71.6%)			
Novel Genes	29 (28.4%)			
Inheritance Pattern	L			
Denovo	64 (62.7%)			
X-linked	5 (4.9%)			
Autosomal Recessive	33 (32.4%)			
Variant Type				
Pathogenic (P)	56 (54.9%)			
Likely Pathogenic (LP)	38 (37.3%)			
VUS/LGD	8 (7.8%)			
Clinical Assessment	:			
Likely	59 (57.8%)			
Possibly	18 (17.6%)			
Unlikely	25 (24.5%)			

#### 183 Discussion

Discerning clinically relevant ASD candidate variants from many variants poses a formidable 184 challenge for clinical experts, demanding considerable time and effort. Here, we present 185 AutScore, a novel bioinformatics prioritization tool that integrates variant and gene-level 186 information to prioritize ASD candidate variants derived from WES data. AutScore can be 187 integrated into an existing bioinformatic pipeline for WES data analysis by pre-installing the 188 ACMG/AMP [10] variant interpretation tool InterVar [14] and our in-house tool Psi-Variant 189 [28]. Although AutScore was initially designed to assess the ASD clinical relevance of rare 190 191 autosomal SNVs, it can be adapted for analyses of copy number variants (CNVs),

mitochondrial variants, and common heritable variants that are expected to enhance itsapplicability further.

Our results indicated that *AutScore* is highly efficient in detecting clinically relevant ASD variants. Using its most effective cut-off (i.e.,  $\geq 12$ ), it achieves an overall diagnostic yield of 11.9%, comparable to results from prior studies [5,21,22]. We showed that *AutScore* outperforms the existing NDD variant prioritization tool, *AutoCasC* [14], in detecting clinically relevant ASD candidate variants. The higher accuracy of *AutScore* compared to *AutoCasC* is likely because it was explicitly designed to detect ASD candidate variants. At the same time, *AutoCasC* focuses on prioritizing candidate variants related to a broader range of NDDs.

201 The following limitations should be considered when using AutScore. First, the AutScore metric was established using a trial-and-error approach, assigning certain weights and penalties 202 203 to its different elements. It is possible to mitigate this inherent subjectivity using a machine 204 learning model-based prioritization score. Since such models require larger datasets of true ASD variants, we plan to upgrade to AutScore when such datasets are available. Second, 205 206 AutScore is constrained to specific genes from the DisGeNET [31] and SFARI Gene [30] databases. Consequently, it might have missed some potential candidate variants in genes not 207 208 cataloged in these databases. Third, the performance of AutScore data has not been assessed in WGS data. Hence, caution should be taken when applying this ranking tool to prioritize ASD 209 210 candidate variants derived from WGS data. Fourth, the estimates derived from AutScore, 211 including accuracy, PPV, and yield, were computed based on WES data from an ASD cohort within the Israeli population. Thus, these estimates could vary in other populations. Lastly, 212 213 AutScore may not function optimally in cases involving probands with incomplete pedigree 214 information and unknown segregation patterns.

#### 215 Conclusion

216 AutScore constitutes a highly effective automated ranking system designed to prioritize ASD

217 candidate genetic variants in WES data. The utilization of *AutScore* holds the potential to 218 significantly streamline the process of elucidating the specific genetic etiology of ASD within 219 affected families. In doing so, it can contribute to expediting and enhancing the accuracy of 220 clinical management and treatment strategies, ultimately leading to more effective 221 interventions in the context of ASD.

# List of abbreviations

ASD: Autism Spectrum Disorder

SNVs: Single Nucleotide Variants

**INDELs:** Insertions/Deletions

LGD: Likely Gene Disrupting

LP/P/VUS: Likely Pathogenic/Pathogenic/Variants of Uncertain Significance

LoF: Loss of Function

**CNVs: Copy Number Variants** 

WES: Whole Exome Sequencing

WGS: Whole Genome Sequencing

ACMG/AMP: American College of Medical Genetics and Genomics/Association of

Molecular Pathology

GATK: Genome Analysis Toolkit

IQR: Interquartile Range

NDDs: Neurodevelopmental Disorders

PPV: Positive Predictive Value

NPV: Negative Predictive Value

SFARI: Simons Foundation Autism Research Initiative

OMIM: Online Mendelian Inheritance in Man

# AUC: Area Under the Curve

**ROC:** Receiver Operating Characteristic

# Declarations

#### **Institutional Review Board Statement**

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Soroka University Medical Center (SOR-076-15; 17 April 2016).

# Ethics approval and consent to participate

Written consent was obtained from all parents of children involved in the study.

# **Consent for publication**

All the data from the registered families presented here are de-identified.

# Availability of data and materials

WES data were generated as part of the ASC and are available in dbGaP with study accession: phs000298.v4.p3. All the codes will be available upon reasonable request to the corresponding author.

#### **Competing interests**

The authors declare no competing interests.

# Funding

This study was funded by the Israel Science Foundation (#1092/21).

#### **Authors' contributions**

*Conceptualization*: A.S. and I.M.; *methodology*: A.S. and I.M.; *software*: A.S. and L.L.; *validation*: N.A. and N.L.; *formal analysis*: A.S.; *resources*: N.S., H.A.K, G.M., A.M., Y.T., A.A., H.G., and I.M.; *data curation*: A.S.; *writing—original draft preparation*: A.S. and I.M.; *writing—review and editing*: I.M., and A.S.; *supervision*: I.M.; *project administration*: I.M.;

*funding acquisition*: I.M. All the authors have read and agreed to the published version of the manuscript.

# Acknowledgments

We thank the families who participated in this research; genetic studies would be impossible without their contributions.

# Authors' information (optional)

#### Reference

- [1] E. Rees et al., 'Schizophrenia, autism spectrum disorders and developmental disorders share specific disruptive coding mutations', Nat Commun, vol. 12, no. 1, pp. 1–9, 2021, doi: 10.1038/s41467-021-25532-4.
- [2] A. W. Zoghbi et al., 'High-impact rare genetic variants in severe schizophrenia,' Proc Natl Acad Sci U S A, vol. 118, no. 51, pp. 1–10, 2021, doi: 10.1073/pnas.2112560118.
- J.-Y. An et al., 'Genome-wide de novo risk score implicates promoter variation in autism [3] spectrum disorder', 2018, doi: 10.1126/science.aat6576.
- S. J. Sanders et al., 'Whole genome sequencing in psychiatric disorders: the WGSPD [4] consortium', Nature Neuroscience 2017 20:12, vol. 20, no. 12, pp. 1661–1668, Nov. 2017, doi: 10.1038/s41593-017-0017-9.
- [5] B. Trost et al., 'Genomic architecture of autism from comprehensive whole-genome sequence annotation', Cell, vol. 185, no. 23, pp. 4409-4427.e18, 2022, doi: 10.1016/j.cell.2022.10.009.
- J. N. Foo, J. J. Liu, and E. K. Tan, 'Whole-genome and whole-exome sequencing in [6] neurological diseases', Nat Rev Neurol, vol. 8, no. 9, pp. 508-517, 2012, doi: 10.1038/nrneurol.2012.148.
- [7] R. K. C. Yuen et al., 'Whole-genome sequencing of quartet families with autism spectrum disorder', Nat Med, vol. 21, no. 2, pp. 185–191, 2015, doi: 10.1038/nm.3792.
- [8] M. S. Reuter et al., 'Diagnostic yield and novel candidate genes by exome sequencing in 152 consanguineous families with neurodevelopmental disorders', JAMA Psychiatry, vol. 74, no. 3, pp. 293–299, 2017, doi: 10.1001/jamapsychiatry.2016.3798.
- [9] A. J. Forstner et al., 'Whole-exome sequencing of 81 individuals from 27 multiply affected bipolar disorder families', Transl Psychiatry, vol. 10, no. 1, 2020, doi: 10.1038/s41398-020-0732-y.
- S. Richards et al., 'Standards and guidelines for the interpretation of sequence variants: A joint [10] consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology', Genetics in Medicine, vol. 17, no. 5, pp. 405–424, 2015, doi: 10.1038/gim.2015.30.
- [11] D. Smedley et al., 'Next-generation diagnostics and disease-gene discovery with the Exomiser', Nat Protoc, vol. 10, no. 12, pp. 2004–2015, 2015, doi: 10.1038/nprot.2015.124.
- J. Birgmeier et al., 'AMELIE speeds Mendelian diagnosis by matching patient phenotype and [12] genotype to primary literature', Sci Transl Med, vol. 12, no. 544, 2020, doi: 10.1126/scitranslmed.aau9113.
- [13] P. N. Robinson et al., 'Interpretable Clinical Genomics with a Likelihood Ratio Paradigm', Am J Hum Genet, vol. 107, no. 3, pp. 403–417, 2020, doi: 10.1016/j.ajhg.2020.06.021.
- B. Popp, J. Lieberwirth, B. Benjamin, C. Kl, and R. A. Jamra, 'AutoCaSc: Prioritizing [14] candidate genes for neurodevelopmental disorders', pp. 1–14, 2022.
- M. Muers, 'Fruits of exome sequencing for autism', Nature Reviews Genetics 2012 13:6, vol. [15] 13, no. 6, pp. 377–377, May 2012, doi: 10.1038/nrg3248.
- J. M. Fu et al., 'Rare coding variation provides insight into the genetic architecture and [16] phenotypic context of autism', Nat Genet, vol. 54, no. September, 2022, doi: 10.1038/s41588-022-01104-0.
- F. K. Satterstrom et al., 'Large-Scale Exome Sequencing Study Implicates Both [17] Developmental and Functional Changes in the Neurobiology of Autism', Cell, vol. 180, no. 3, pp. 568-584.e23, 2020, doi: 10.1016/j.cell.2019.12.036.
- R. K. C. Yuen et al., 'Whole genome sequencing resource identifies 18 new candidate genes [18] for autism spectrum disorder', Nat Neurosci, vol. 20, no. 4, pp. 602-611, 2017, doi: 10.1038/nn.4524.
- [19] H. Guo et al., 'Genome sequencing identifies multiple deleterious variants in autism patients with more severe phenotypes', Genetics in Medicine, vol. 21, no. 7, pp. 1611–1620, 2019, doi: 10.1038/s41436-018-0380-2.
- Y. H. Jiang *et al.*, 'Detection of clinically relevant genetic variants in autism spectrum disorder [20] by whole-genome sequencing', Am J Hum Genet, vol. 93, no. 2, pp. 249-263, 2013, doi: 10.1016/j.ajhg.2013.06.012.

- [21] B. Mahjani et al., 'Prevalence and phenotypic impact of rare potentially damaging variants in autism spectrum disorder', Mol Autism, vol. 12, no. 1, pp. 1-12, 2021, doi: 10.1186/s13229-021-00465-3.
- [22] K. Tammimies et al., 'Molecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing in children with autism spectrum disorder', JAMA - Journal of the American Medical Association, vol. 314, no. 9, pp. 595–903, 2015, doi: 10.1001/jama.2015.10078.
- I. Dinstein et al., 'The National Autism Database of Israel: a Resource for Studying Autism [23] Risk Factors, Biomarkers, Outcome Measures, and Treatment Efficacy', Journal of Molecular *Neuroscience*, vol. 70, no. 9, pp. 1303–1312, 2020, doi: 10.1007/s12031-020-01671-z.
- [24] G. Meiri et al., 'Brief Report: The Negev Hospital-University-Based (HUB) Autism Database', J Autism Dev Disord, vol. 47, no. 9, pp. 2918–2926, 2017, doi: 10.1007/s10803-017-3207-0.
- [25] F. K. Satterstrom, J. A. Kosmicki, J. Wang, K. Roeder, M. J. Daly, and J. D. Buxbaum, 'Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism Article Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism', Cell, pp. 1-17, 2020, doi: 10.1016/j.cell.2019.12.036.
- [26] A. McKenna et al., 'The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data', Genome Res, vol. 20, no. 9, p. 1297, Sep. 2010, doi: 10.1101/GR.107524.110.
- [27] N. A. Miller et al., 'A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases', Genome Med, vol. 7, no. 1, pp. 1–16, Sep. 2015, doi: 10.1186/S13073-015-0221-8/FIGURES/4.
- [28] A. Shil et al., 'Comparison of three bioinformatics tools in the detection of ASD candidate variants from whole exome sequencing data', Scientific Reports /, vol. 13, p. 18853, 123AD, doi: 10.1038/s41598-023-46258-x.
- [29] Q. Li and K. Wang, 'InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines', Am J Hum Genet, vol. 100, no. 2, pp. 267-280, 2017, doi: 10.1016/j.ajhg.2017.01.004.
- [30] B. S. Abrahams et al., 'SFARI Gene 2.0: A community-driven knowledgebase for the autism spectrum disorders (ASDs)', Mol Autism, vol. 4, no. 1, pp. 2-4, 2013, doi: 10.1186/2040-2392-4-36.
- [31] J. Piñero et al., 'DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants', Nucleic Acids Res, vol. 45, no. D1, pp. D833–D839, 2017, doi: 10.1093/nar/gkw943.
- P. C. Ng and S. Henikoff, 'SIFT: Predicting amino acid changes that affect protein function', [32] Nucleic Acids Res, vol. 31, no. 13, pp. 3812–3814, 2003, doi: 10.1093/nar/gkg509.
- I. Adzhubei, D. M. Jordan, and S. R. Sunyaev, Predicting functional effect of human missense [33] mutations using PolyPhen-2, vol. 2, no. SUPPL.76. 2013. doi: 10.1002/0471142905.hg0720s76.
- [34] P. Rentzsch, D. Witten, G. M. Cooper, J. Shendure, and M. Kircher, 'CADD: Predicting the deleteriousness of variants throughout the human genome', Nucleic Acids Res, vol. 47, no. D1, pp. D886–D894, 2019, doi: 10.1093/nar/gky1016.
- N. M. Ioannidis et al., 'REVEL: An Ensemble Method for Predicting the Pathogenicity of [35] Rare Missense Variants', Am J Hum Genet, vol. 99, no. 4, pp. 877-885, 2016, doi: 10.1016/j.ajhg.2016.08.016.
- [36] K. A. Jagadeesh et al., 'M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity', Nat Genet, vol. 48, no. 12, pp. 1581–1586, 2016, doi: 10.1038/ng.3703.
- [37] K. E. Samocha et al., 'Regional missense constraint improves variant deleteriousness prediction', bioRxiv, 2017, doi: 10.1101/148353.
- [38] M. Quinodoz, B. Royer-Bertrand, K. Cisarova, S. A. Di Gioia, A. Superti-Furga, and C. Rivolta, 'DOMINO: Using Machine Learning to Predict Genes Associated with Dominant Disorders', Am J Hum Genet, vol. 101, no. 4, pp. 623-629, 2017, doi:

10.1016/j.ajhg.2017.09.001.

- [39] M. J. Landrum et al., 'ClinVar: improving access to variant interpretations and supporting evidence', Nucleic Acids Res, vol. 46, no. D1, pp. D1062-D1067, Jan. 2018, doi: 10.1093/NAR/GKX1153.
- J. T. Robinson et al., 'Integrative genomics viewer', Nature Biotechnology 2011 29:1, vol. 29, [40] no. 1, pp. 24–26, Jan. 2011, doi: 10.1038/nbt.1754.